z-logo
open-access-imgOpen Access
Serotonin 5-HT3 Receptor Antagonist for Treatment of Severe Diabetic Diarrhea
Author(s) -
Satoshi Murao,
Hitoshi Hosokawa
Publication year - 2010
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc09-2131
Subject(s) - medicine , diabetes mellitus , antagonist , diarrhea , receptor antagonist , serotonin , endocrinology , gastroenterology , pharmacology , receptor
Diabetic diarrhea is a troublesome gastrointestinal complication of diabetes. This condition persists for several weeks to months, and it frequently accompanies fecal incontinence. The cause of diabetic diarrhea is not fully understood, but autonomic neuropathy is thought to be an underlying mechanism (1). Parenteral somatostatin analog octreotide has been shown to be useful in the treatment of severe long-standing diabetic diarrhea (1). Selective serotonin 5-hydroxy tryptamine type 3 (HT3) receptor antagonist, which was developed as an antiemetic in cancer chemotherapy, prolongs colonic transit, inhibits small bowel secretion, and decreases colonic compliance (2). Here, we report the underlying mechanism of ramosetron (2 …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom